EUVIMEDEUVIMED entdecken
Leserbrief

Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514)

Carole Soussain, Denis Malaise, Sylvain Choquet, Hervé Ghesquières, Caroline Houillier

European Journal of Cancer · 2023

DOI: 10.1016/j.ejca.2023.04.025 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Carole Soussain und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Institut Curie, Site Saint-Cloud, Saint-Cloud, France. Electronic address: carole.soussain@curie.fr. Hauptthemen laut MEDLINE: Retinal Neoplasms, Lymphoma, Central Nervous System Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Retinal NeoplasmsLymphomaCentral Nervous System NeoplasmsHumansNeoplasm Recurrence, LocalVitreous BodyChronic DiseaseAdeninePiperidines

Substanzen

ibrutinibAdeninePiperidines

Autor:innen und Institutionen

  • Hematology, Institut Curie, Site Saint-Cloud, Saint-Cloud, France. Electronic address: carole.soussain@curie.fr.
  • Ophthalmology, Institut Curie, Site Paris, Université Paris V Descartes et PSL (Paris Science et Lettre), Paris, France.
  • Hematology, APHP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
  • Hematology, Centre Hospitalier Lyon Sud, Université Claude Bernard Lyon 1, Pierre-Bénite, France.
  • APHP, Sorbonne Université, IHU, ICM, Neurology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

Zitieren

APA

Soussain, C., Malaise, D., Choquet, S., Ghesquières, H., & Houillier, C. (2023). Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.04.025

Vancouver

Soussain C, Malaise D, Choquet S, Ghesquières H, Houillier C. Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514). European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.04.025

BibTeX
@article{Soussain2023,
  author = {Soussain, Carole and Malaise, Denis and Choquet, Sylvain and Ghesquières, Hervé and Houillier, Caroline},
  title = {Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514)},
  journal = {European Journal of Cancer},
  year = {2023},
  doi = {10.1016/j.ejca.2023.04.025}
}
Kostenlos starten →